Antimetastatic activities of heparins and modified heparins. Experimental evidence.
about
Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanaseTargeting Selectins and Their Ligands in CancerTFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like responseHeparin modulates the conformation and signaling of platelet integrin αIIbβ3Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice.Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.Selective interaction of heparin with the variable region 3 within surface glycoprotein of laboratory-adapted feline immunodeficiency virusThe emerging importance of α-L-fucose in human breast cancer: a review.Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparinsCirculating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent ApproachesThe antineoplastic effect of low-molecular-weight heparins - a literature reviewHeparin and related drugs: beyond anticoagulant activity.The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis.Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery.New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients.A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.Over-sulfated glycosaminoglycans are alternative selectin ligands: insights into molecular interactions and possible role in breast cancer metastasis.Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?In vitro effects of Apixaban on 5 different cancer cell lines.D-dimer as a potential prognostic marker.Effects of surface charge of low molecular weight heparin-modified cationic liposomes on drug efficacy and toxicity.The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.In Vivo MR Imaging of Fibrin in a Neuroblastoma Tumor Model by Means of a Targeting Gd-Containing Peptide.ALK1 expression in oral lichen planus: a possible relation to microvessel density.Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
P2860
Q24605311-6F3AA171-6D61-48CC-A195-2ADE38A5ABAEQ26752384-2D0BD05F-BB95-4C9B-B4A5-3069D0562615Q28539226-6BEFBA64-DCC0-4972-A983-1CB692D16720Q30513893-27DC3656-2ADA-4812-962C-F8CE04810F1AQ33399333-A209A84A-2AC0-4FFB-A25D-0194E8796B98Q34119737-AEF16BA5-AC9F-4A84-940F-80663AF32F9DQ34388854-2D71E790-52E3-4004-9344-4F53B281CF05Q34734101-70776B62-B0E1-4307-8B33-7B5C44D72223Q35172546-FF516AAE-31CD-4C39-BAB5-8E7B694591C5Q35810537-363BEBE9-6BC8-4B0C-A9C6-C117F3ADD97DQ36255936-65AE9F13-4896-4A5D-92E5-F3B978AAB5E9Q36936771-ABB36E58-E7B4-4812-ADDF-071C2530F858Q37105310-55E71858-A51B-4E5B-8D6E-B4B4C72B1BCEQ37129768-CD4B4625-0276-492C-B651-E3298ADCA6EFQ37708829-6768BC4D-36D0-49EA-998B-E73B39DE88B5Q37866790-AF777EFC-C82A-456C-B577-3CD823A010A6Q38011258-8099F7D9-442E-471D-8C29-859A2AE94EA0Q38223377-321D9CC3-AEFA-4B0F-9140-049C3D92BF33Q38925364-6376DFD9-1D82-4CFE-ABB8-1D200A5DBE0BQ39143578-A9E46035-7093-4F3A-A137-0DB0958E7DB4Q39359007-46EAE7AA-746E-46A5-BDE3-8952EB1B6B73Q40671371-46AD1B37-ED9C-4DF4-AA7D-809AD24B5E12Q42117301-BBD867C5-63FD-4F2E-A858-724362FA908BQ42375694-4D8E6374-B45A-4F90-A4BA-9112679272E6Q44578606-A7225FCC-3B04-4AE9-ABA2-C36E4EB31EBBQ47229769-3AE6C816-F914-47BD-93F2-EE4EFBAC0EAFQ48218215-D49EC9A3-44F8-42C7-A95B-12E00CACDEA5Q50988945-8E2AAD40-9B6C-463B-997F-ECF00D7E5954Q53780231-CE3AAFC5-6C2C-4164-99CB-977C07A7858FQ55058467-DEADDA8D-A5C5-4E70-90F0-62568A4C7FDC
P2860
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@en
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@nl
type
label
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@en
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@nl
prefLabel
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@en
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
@nl
P1433
P1476
Antimetastatic activities of heparins and modified heparins. Experimental evidence
@en
P2093
Lubor Borsig
P304
P356
10.1016/S0049-3848(10)70017-7
P478
125 Suppl 2
P50
P577
2010-04-01T00:00:00Z